At a glance
ClinicalIndex Comparison Record- ✓Relapsed, refractory, or high-risk CD-20-positive B-cell NHL or CLL (including Richter's transformation or high-risk chromosomal abnormalities in CLL)
- ✓Measurable disease
- ✓Age 18-70 years with expected survival ≥3 months
- ✓ECOG performance status 0-2
- ✕Prior myeloablative therapies or radioimmunotherapy
- ✕Prior external beam radiation therapy to >25% of active bone marrow
- ✕Prior therapy with 90Y Zevalin or Campath
- ✕CNS lymphoma, HIV, or HTLV-1 positivity
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
In Brief
A Phase 2 clinical trial evaluating Zevalin Radioimmunotherapy, Rituximab, and 3 other interventions for Lymphoma and Leukemia. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of remission in patients with leukemia and lymphoma. The safety of this treatment will also be studied.
Study Details
Timeline
Interventions
Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
250 mg/m\^2 on day 1 and day 8
30 mg/m\^2/day for 3 days
750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
Allogeneic stem cell transplantation 2 days after chemotherapy